EGFR and non-small cell lung carcinoma: A phase III, randomized, multicenter, open-label study, FURMO-004 (NCT05607550), evaluating furmonertinib versus platinum-containing chemotherapy in the first-line treatment of EGFR ex20ins mutations NSCLC is ongoing (51).